His research investigates the comparative- and cost-effectiveness of interventions to identify and treat HIV and HCV, employing methods of computational biology and clinical epidemiology. His aim is to maximize the benefits of evolving therapies for HIV and HCV in the “real-world”, where resources are constrained and the best methods for managing infected individuals are not certain.